The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
Reinforcing commitment to ethical and sustainable growth
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Subscribe To Our Newsletter & Stay Updated
